Cipla Signs an Exclusive License Agreement with Bio-Thera for its BAT1706 (bevacizumab, biosimilar)

 Cipla Signs an Exclusive License Agreement with Bio-Thera for its BAT1706 (bevacizumab, biosimilar)

Cipla Signs an Exclusive License Agreement with Bio-Thera for its BAT1706 (bevacizumab, biosimilar)

Shots:
  • Cipla to get exclusive commercialization rights for Bio-Thera’s BAT1706 in certain countries. Bio-Thera will be responsible for its development & product approval with FDA & EMA
  • In 2020, Bio-Thera plans to file an NDA to NMPA (CMPA), EMA and the US FDA for BAT1706 approval
  • Avastin’s biosimilar BAT1706 is a mAb, evaluated in P-III for patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC) and is approved in six indications including metastatic colorectal cancer (m CRC), recurrent glioblastoma and non-squamous non-small cell lung cancer (NSCLC)
Click here to read full press release/ article | Ref: Businesswire| Image: Cipla Blog

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post